<DOC>
	<DOCNO>NCT00005703</DOCNO>
	<brief_summary>To assess old child adult sickle cell disease ( SCD ) whether intrinsic activation ( relevant origin pain acute inflammation ) occur vasocclusive crisis ( VOC ) .</brief_summary>
	<brief_title>Hemostasis Sickle Cell Disease -- Infancy Adulthood</brief_title>
	<detailed_description>BACKGROUND : Investigations hemostatic abnormality associate sickle cell disease numerous . The data suggest thrombin generation fibrin formation increase steady state , conflict data whether activation occur vaso-occlusive crisis . Platelet activation VOC occur , variable finding steady state . A selective , concomitant evaluation hemostatic pathway i.e . intrinsic , tissue factor ( TF ) extrinsic activation , fibrinolysis , platelet-endothelial activation report . Neither longitudinal evaluation perform infant unique transition period HbF level fall 70 80 percent less 10 percent . The study part initiative `` Coagulation , Platelets Thrombosis Sickle Disease Pathophysiology '' . The Request Applications release October 1994 . DESIGN NARRATIVE : The study use appropriate 'negative ' 'positive ' control group . Studies include intrinsic marker [ kininogen profiling , high molecular weight kininogen ( HK ) low molecular weight kininogen ( LK ) cleavages , western blot HK LK , kallikrein-alpha2 macroglobulin ; extrinsic marker [ TF factor V11a ] ; activation fibrinolytic marker [ prothrombin F1.2 , FPA , TAT , tPA , PAI-I , D-dimer plasma alpha2 antiplasmin ] ; platelet- endothelial marker [ evaluation activation dependent epitope ] . Unequivocal demonstration contact pathway activation VOC provide crucial link VOC accompany phenomenon include pain , inflammation . Finally , study provide unique perspective continuum hemostatic change unfold course SCD , develop vascular insufficiency supervene adult . The study completion date list record obtain `` End Date '' enter Protocol Registration Results System ( PRS ) record .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<criteria>No eligibility criterion</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2005</verification_date>
</DOC>